A Pilot Clinical Trial of Sodium Thiosulfate (STS) for Prevention of Ototoxicity in Patients with Locally Advanced Squamous Cell Carcinoma of Head and Neck (SCCHN) Undergoing Concurrent Chemoradiation with Cisplatin

Ototoxicity is a well described side effect of cisplatin and up to 88% of SCCHN patients undergoing chemoradiation develop some degree of hearing loss. Clinical trials in pediatric cancer patients receiving high cumulative doses of cisplatin have demonstrated that use of STS infusion 4-8 hours after cisplatin administration led to a significantly lower likelihood of hearing loss. We therefore conducted a prospective pilot clinical trial to assess the feasibility and safety of intravenous STS after cisplatin in locally advanced SCCHN patients undergoing concurrent chemoradiation with cisplatin.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: 164 Source Type: research